Cybin Completes US$175-Million Registered Direct Offering

On October 31, 2025, Cybin Inc. (CBOE: CYBN) (NYSE American: CYBN), a breakthrough Phase 3 clinical stage neuropsychiatry company committed to revolutionizing mental healthcare, completed a registered direct offering of 22,277,750 common shares in the capital of the company (a “Common Share”) and, in lieu of Common Shares to certain investors, pre-funded Common Share purchase warrants (the “Pre-Funded Warrant”) at a price of US$6.51 per Common Share or Pre-Funded Warrant for aggregate gross proceeds of US$175,009,911.45. Each Common Share and each Pre-Funded Warrant was accompanied by 0.35 of one Common Share purchase warrant.

The financing included new and existing investors, including Venrock Healthcare Capital Partners, OrbiMed, Point72, Deep Track Capital, Acorn Bioventures, Spruce Street Capital, Squadron Capital Management, Adage Capital Partners LP, Boxer Capital Management, ADAR1 Capital Management, Stonepine Capital Management, Pivotal Bioventure Partners and Ally Bridge Group.

Jefferies, TD Cown and Cantor acted as joint lead placements agents and Bloom Burton Securities Inc. acted as placement agent for the offering. Cybin intends to use the net proceeds from the offering to repay its outstanding unsecured convertible debentures, to progress its CYB003, CYB004 and CYB005 programs, and for working capital and general corporate purposes.

Aird & Berlis represented Cybin with a team led by Sherri Altshuler and including Danny Kharazmi, Sean Green, Meredith McCann, Liam Tracey-Raymont, Karlie Nordstrom, Teddy Nikolaou and Ali Kwinter (Capital Markets) and Manjit Singh (Tax).